BACKGROUND: Many @entity1 present with refractory @entity159 ( @entity159 ) despite multiple @entity302 ( @entity302 ). @entity13876 (LCM) was recently approved as an adjunct AED for partial-onset @entity410 . It has unique mechanism of modulating voltage-gated @entity1372 channels by enhancing their slow inactivation. LCM has demonstrated efficacy in animal models of pharmacoresistant @entity410 . To date, there are isolated anecdotal reports of LCM use in @entity159 . OBJECTIVE: To report a single center experience with IV @entity13876 in @entity1 with NCSE. METHODS: Pharmacy records were reviewed to identify @entity1 with @entity159 who received IV LCM in our institution. Data on demographics, response to therapy and adverse effects/outcomes were analyzed. All @entity1 had continuous EEG monitoring. RESULTS: 10 @entity1 (4 @entity1 , 6 @entity1 ), age 16-90 years with refractory @entity159 were given LCM. Eight @entity1 were in focal non-convulsive @entity159 (NCSE), 2 were in generalized non-convulsive @entity159 . The etiologies included @entity1545 , idiopathic, @entity198 , @entity5 , @entity75 ( @entity75 ), @entity64 , and @entity7026 . IV LCM was added after traditional @entity302 , including drug-induced @entity772 in some, failed to control the @entity159 . NCSE resolved in 7/10 @entity1 whereas 1/10 @entity1 showed partial response with cessation of NCSE but still frequent electrographic @entity410 and 2/10 @entity1 were resistant to therapy. CONCLUSIONS: LCM is a useful adjunct in refractory NCSE. The IV formulation allows prompt administration in the intensive care unit setting. Response was seen especially in focal @entity159 . Similar to other @entity302 , response was poor in @entity1 with @entity130 . Our data is limited by the small number of @entity1 . Larger controlled studies are necessary to assess accurately the efficacy of IV LCM as an early treatment of @entity159 .

Intravenous XXXX in refractory nonconvulsive @entity159 .

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'men'] @entity1545 :: ('MESH:D020214', 'Disease') :: ['anoxic brain injury'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity7026 :: ('MESH:D002538', 'Disease') :: ['AVM'] @entity198 :: ('MESH:D004660', 'Disease') :: ['encephalitis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity75 :: ('MESH:D001927', 'Disease') :: ['PRES', 'posterior reversible encephalopathy syndrome'] @entity1372 :: ('MESH:D012964', 'Chemical') :: ['sodium'] @entity772 :: ('MESH:D003128', 'Disease') :: ['coma'] @entity13876 :: ('MESH:C403507', 'Chemical') :: ['Lacosamide'] @entity302 :: ('MESH:D004827', 'Disease') :: ['AEDs', 'anti-epileptic drugs'] @entity159 :: ('MESH:D013226', 'Disease') :: ['SE', 'Status epilepticus'] @entity130 :: ('MESH:D014947', 'Disease') :: ['postanoxic injury']
@entity13876 :: (MESH:C403507,Chemical) :: ['Lacosamide']
